Healthcare 4 March 2026 - 1 April 2026

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
···

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK completed a reshaping of ViiV Healthcare’s ownership on April 1, with Shionogi raising its stake to 21.7% after Pfizer exited the HIV-focused venture. ViiV issued new shares to Shionogi for $2.125 billion and cancelled Pfizer’s holding. GSK retained a 78.3% majority and took a $250 million special dividend. The deal extinguished a put option liability tied to the old structure.
April 2, 2026
GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake
···

GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake

Shionogi increased its stake in ViiV Healthcare to 21.7% as Pfizer exited, leaving GSK with a 78.3% majority. ViiV issued new shares to Shionogi for $2.125 billion and paid Pfizer $1.875 billion. GSK received a $250 million special dividend and removed an accounting liability tied to Pfizer’s exit. The transaction followed Chinese approval of GSK’s asthma drug Exdensur.
April 1, 2026
4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push
···

4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push

4DMedical said Friday its CT:VQ lung imaging software won CE mark clearance in the EU and secured A$83 million in a private placement at A$5.90 a share. The company expects to have A$289 million in cash at year-end 2025. Mayo Clinic began using CT:VQ on March 25, joining five other U.S. academic centers since FDA clearance in September. Shares closed at A$6.28 after touching A$7.55 intraday.
March 29, 2026
GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects
···

GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK shares rose 0.54% to 2,056 pence in London after the European Medicines Agency agreed to review its experimental hepatitis B drug, bepirovirsen. The company said Phase III trials showed higher functional cure rates when bepirovirsen was added to standard care. The drug is not yet approved. JPMorgan maintained a sell rating, with a target price near current levels.
March 27, 2026
GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod
···

GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod

GSK shares climbed 3.2% to 2,039.5 pence in London after Japan granted orphan-drug status to its lung-cancer therapy risvutatug rezetecan and a filing showed continued share buybacks. The stock rose above 2,000 pence, aided by broader FTSE 100 gains. Analysts at Deutsche Bank and Barclays maintained price targets below current levels, citing mixed signals from recent drug launches.
March 25, 2026
CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds
···

CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds

CSL Limited has begun a $1.5 billion expansion of its Kankakee, Illinois, manufacturing site, aiming to add at least 300 jobs and boost plasma-derived therapy output by 2031. The move follows an 81% drop in first-half profit and recent leadership changes. CSL also repurchased 62,472 shares for about A$9.1 million on March 10. Shares closed at A$144.56 Tuesday, up 1.65% but near a 52-week low.
March 11, 2026
Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools
···

Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools

Pro Medicus’ U.S. unit renewed two imaging software contracts totaling at least A$40 million, including a five-year, A$31 million extension with MedStar Health that adds heart-imaging tools, and a separate A$9 million deal with Zwanger-Pesiri. Both contracts were signed at higher per-transaction fees and expand the company’s presence in the U.S. market.
March 11, 2026
JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead
···

JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead

A federal judge in Manhattan allowed JPMorgan Chase employees to pursue key claims in a proposed class action alleging the bank mismanaged its health and prescription benefits plan, leading to inflated drug and premium costs. The suit claims the plan paid markups averaging 211% on 366 generic drugs through CVS Caremark. JPMorgan declined to comment. The judge dismissed some fiduciary-duty claims but let prohibited-transaction claims proceed.
March 10, 2026
UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event
···

UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event

A congressional committee found seniors paid about 10% more in Medicare Part B premiums last year due to alleged overpayments to private Medicare Advantage plans, the Wall Street Journal reported Tuesday. UnitedHealth shares fell 1.4% by midmorning. The company, the largest Medicare Advantage provider, is set to address investors at a Barclays conference later in the day. UnitedHealth has denied previous allegations of aggressive billing practices.
March 10, 2026
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets
···

Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets

Biohaven Ltd shares swung sharply Monday, opening at $11.38, peaking at $12.70, then dropping to $9.91 by 10:55 a.m. EDT, with volume over 3.1 million. The moves followed a leadership change at the FDA, which last year rejected Biohaven’s rare-disease drug Vyglxia, sending shares down over 40%. Biohaven reported a 2025 net loss of $738.8 million and ended December with $322 million in cash.
March 9, 2026
Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI
···

Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI

Amazon Web Services launched Amazon Connect Health, an AI service for healthcare administration, on Thursday. The tool integrates with Epic electronic health records to verify patients, schedule visits, and generate billing codes. Patient verification and ambient documentation are available now; other features remain in preview. AWS says UC San Diego Health cut call abandonment by 30% using the system.
March 6, 2026
CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares
···

CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL’s Seqirus unit has secured a Canadian government contract to supply up to 15 million pandemic flu vaccine doses from its Tullamarine plant if a pandemic is declared. The deal follows an 81% drop in CSL’s half-year profit and a leadership change. Financial terms were not disclosed. CSL has spent about A$738.8 million on share buybacks since launching its on-market program.
March 6, 2026
Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap
···

Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap

Eli Lilly launched “Employer Connect” to let U.S. employers offer its obesity drug Zepbound at network pharmacies for $449 per dose. Partners include GoodRx, Teladoc Health, and Mark Cuban Cost Plus Drug Company. Lilly shares fell about 2% after the announcement. The company said final out-of-pocket costs will depend on each employer’s cost-sharing model.
March 6, 2026
Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork
···

Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork

Amazon Web Services on Thursday launched Amazon Connect Health, an AI platform that automates tasks like appointment scheduling and billing by integrating with electronic health records. Patient verification and ambient documentation are available now; other features are in preview. Early use at UC San Diego Health cut call abandonment by up to 60%. AWS said clinicians must review all AI-generated outputs.
March 5, 2026
Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push
···

Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push

Bradesco filed a distance voting ballot for a March 31 shareholders’ meeting to seek approval for a partial spin-off of Bradseg Participações. The move is part of a plan to transfer health assets into Odontoprev, which would become Bradsaúde. Bradesco’s New York-listed shares fell 6.6% after the filing. Shareholder approval and regulatory clearance are still required.
March 4, 2026
1 2 3 4